MX2015008298A - Metodo de tratamiento usando lactobacillus fermentum me-3. - Google Patents

Metodo de tratamiento usando lactobacillus fermentum me-3.

Info

Publication number
MX2015008298A
MX2015008298A MX2015008298A MX2015008298A MX2015008298A MX 2015008298 A MX2015008298 A MX 2015008298A MX 2015008298 A MX2015008298 A MX 2015008298A MX 2015008298 A MX2015008298 A MX 2015008298A MX 2015008298 A MX2015008298 A MX 2015008298A
Authority
MX
Mexico
Prior art keywords
level
lactobacillus fermentum
decreasing
treatment
preventing
Prior art date
Application number
MX2015008298A
Other languages
English (en)
Inventor
Tiiu Kullisaar
Mihkel Zilmer
Imbi Smidt
Kersti Zilmer
Marika Mikelsaar
Pirje Hütt
Original Assignee
Univ Tartu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tartu filed Critical Univ Tartu
Publication of MX2015008298A publication Critical patent/MX2015008298A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
    • A23G1/42—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G1/423—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/143—Fermentum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona una composición que comprende cepa DSM 14241 de Lactobacillus fermentum ME-3 para uso en la prevención, el alivio de síntomas de o el tratamiento, sólo o como un componente adyuvante, de un trastorno relacionado con síndrome metabólico seleccionado a partir de prediabetes, diabetes tipo 2 y enfermedad cardiovascular. El efecto puede ser alcanzado a disminuir simultáneamente el nivel de hemoglobina glucosilada HbA1c, disminuir o prevenir la inflamación de bajo grado a nivel celular y aumentar el nivel de adiponectina.
MX2015008298A 2012-12-24 2013-12-20 Metodo de tratamiento usando lactobacillus fermentum me-3. MX2015008298A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1223370.6A GB201223370D0 (en) 2012-12-24 2012-12-24 Method of treatment using lactobacillus fermentum ME-3
PCT/IB2013/061216 WO2014102692A1 (en) 2012-12-24 2013-12-20 Method of treatment using lactobacillus fermentum me-3

Publications (1)

Publication Number Publication Date
MX2015008298A true MX2015008298A (es) 2016-06-06

Family

ID=47682578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008298A MX2015008298A (es) 2012-12-24 2013-12-20 Metodo de tratamiento usando lactobacillus fermentum me-3.

Country Status (17)

Country Link
US (1) US9974817B2 (es)
EP (1) EP2943210B8 (es)
JP (1) JP6484561B2 (es)
AU (1) AU2013368969B2 (es)
BR (1) BR112015014334A2 (es)
CA (1) CA2896278C (es)
DK (1) DK2943210T3 (es)
ES (1) ES2649969T3 (es)
GB (1) GB201223370D0 (es)
HK (1) HK1216141A1 (es)
LT (1) LT2943210T (es)
MX (1) MX2015008298A (es)
PH (1) PH12015501425A1 (es)
PL (1) PL2943210T3 (es)
RU (1) RU2015130679A (es)
SG (1) SG11201504787VA (es)
WO (1) WO2014102692A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018104263A1 (en) * 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
CN110475853A (zh) * 2017-01-13 2019-11-19 益福生医股份有限公司 新颖乳酸菌及其应用
KR101980527B1 (ko) * 2018-03-26 2019-05-21 주식회사 지놈앤컴퍼니 신규한 락토바실러스 퍼멘텀 lm1016 균주, 및 이를 포함하는 심혈관질환 예방 또는 치료용 조성물
US11484557B2 (en) * 2018-08-31 2022-11-01 Mediogen Co., Ltd. Human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244 strain having anti-obesity activity, and composition comprising same
KR101937758B1 (ko) * 2018-09-05 2019-01-11 마이크로바이오주식회사 락토바실러스 퍼멘텀 ubc-u32, 및 이의 퇴행성 뇌질환 예방 및 치료 용도
JP2023507893A (ja) * 2019-12-31 2023-02-28 ジーアイ バイオーム ラクトバチルス・ファーメンタム株、及びそれを含有する、代謝疾患を防止又は処置するための組成物
EP4086335A4 (en) * 2019-12-31 2023-10-11 Gi Biome LACTOBACILLUS FERMENTUM STRAIN, AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF METABOLIC DISEASES, INCLUDING THE SAME
US20230285478A1 (en) * 2021-10-19 2023-09-14 Tci Co., Ltd. Method of lactobacillus fermentum tci757 for reducing fat and gaining muscle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
EE04580B1 (et) 2001-06-29 2006-02-15 Tartu �likool Mikroorganismi tüvi Lactobacillus fermentum ME-3 kui antimikroobne ja antioksüdantne probiootikum
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus
AU2009220403B2 (en) 2008-03-07 2015-02-26 Megmilk Snow Brand Co., Ltd. Agents for promoting secretion and/or suppressing decrease of adiponectin

Also Published As

Publication number Publication date
EP2943210B8 (en) 2018-01-10
GB201223370D0 (en) 2013-02-06
LT2943210T (lt) 2017-12-11
PL2943210T3 (pl) 2018-02-28
EP2943210A1 (en) 2015-11-18
AU2013368969A1 (en) 2015-07-09
DK2943210T3 (en) 2018-01-02
BR112015014334A2 (pt) 2017-07-11
SG11201504787VA (en) 2015-07-30
US20150343003A1 (en) 2015-12-03
JP2016511742A (ja) 2016-04-21
WO2014102692A1 (en) 2014-07-03
CA2896278A1 (en) 2014-07-03
HK1216141A1 (zh) 2016-10-21
US9974817B2 (en) 2018-05-22
JP6484561B2 (ja) 2019-03-13
PH12015501425A1 (en) 2015-09-14
CA2896278C (en) 2018-09-04
ES2649969T3 (es) 2018-01-16
EP2943210B1 (en) 2017-10-04
AU2013368969B2 (en) 2018-06-14
RU2015130679A (ru) 2017-01-26

Similar Documents

Publication Publication Date Title
PH12015501425A1 (en) Method of treatment using lactobacillus fermentum me-3
WO2008098192A3 (en) Compositions and methods for treating neuropathy
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
PH12015502275B1 (en) Therapuetic uses of empagliflozin
EP3723775A4 (en) MICROBIAL COMPOSITIONS AND METHODS OF TREATMENT OF TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME
PH12015502310B1 (en) Pharmaceutical composition, methods for treating and uses thereof
EP2621282A4 (en) GABA AGONISTS FOR THE TREATMENT OF DISEASES RELATED TO THE METABOLIC SYNDROME AND GABA COMBINATIONS FOR THE TREATMENT OR PROPHYLAXIS OF DIABETES TYPE I
PH12015501291A1 (en) Functionalized exendin-4 derivatives
MX2010004488A (es) Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.
WO2013177594A3 (en) Xylitol-based anti-mucosal compositions and related methods and compositions
WO2010065491A3 (en) Methods of treating inflammatory disorders
WO2012145651A3 (en) Compounds for the treatment of neuropsychiatric disorders
MY188344A (en) Extract formulations of rhodamnia cinerea and uses thereof
WO2010015929A3 (en) Uses of mesenchymal stem cells
PH12015502102A1 (en) Reducing proinflammatory response
WO2015034812A3 (en) A new ketogenic diet and its use in treating the critically ill
WO2012170947A3 (en) Methods for modulating factor 12 expression
WO2010138393A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2012170945A3 (en) Methods for modulating kallikrein (klkb1) expression
WO2015003122A3 (en) Regulation of glucose metabolism using anti-cgrp antibodies
WO2008016730A3 (en) Compositions and methods for reducing cellular fat
MX2012014163A (es) Uso de acido sialico, precursor de acido sialico o una combinacion de los anteriores para preparar medicamentos utiles en una condicion diabetica o sindrome nefrotico.
EP1865778A4 (en) METHOD FOR AVOIDING OEDEM IN THE TREATMENT OF METABOLISM DISORDER, INFLAMMATORY DISEASES AND CARDIOVASCULAR DISEASES
WO2013037943A8 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
WO2010138389A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin